# A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis

> **NCT06921759** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 206 (estimated)

## Conditions studied

- Atopic Hand and Foot Dermatitis

## Interventions

- **DRUG:** Lebrikizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06921759
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-04-21
- **Primary completion:** 2026-05
- **Final completion:** 2026-07
- **Target enrollment:** 206 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06921759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06921759, "A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06921759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*